IPI updates
Quick facts
- IPI was founded in 2017 by scientists Tim Springer and Andrew Kruse of Harvard Medical School.
- The Institute is headquartered on the Harvard Medical School campus in Boston’s Longwood Medical and Academic Area.
- IPI is making synthetic recombinant antibodies and distributing them to scientists through its nonprofit partner Addgene.
- IPI is financially secured by substantial gifts from co-founder Tim Springer, revenue from antibody distribution, sponsored research and federal funding.
- IPI employs approximately 40 people, mostly scientists and research associates staffing its antibody platform.
- IPI is a nonprofit 501(c)3 organization.
About IPI
IPI’s mission is to accelerate research and improve human health by providing scientists with openly shared protein tools capable of illuminating fundamental biological processes.
At IPI’s core is a scientific platform matching rare, state-of-the-art technology with skilled scientists from top institutions around the world.
Our scientists apply their protein expertise to scalable, multidisciplinary projects that focus on the basic molecular processes that drive human biology, especially in neurobiology, immunology and cancer.
“I started IPI to go beyond the limitations of antibodies made in animals with a new type of antibody made in yeast. That vision hasn’t changed.”
IPI in the spotlight
The Wall Street Journal
In Vivo
Contact our communications team
Our communications team is happy to work with journalists to share compelling stories.
If you’re a member of the press or media, get in touch with our team at:
